Alyssum Therapeutics is developing AT1965, a small molecule that inhibits CMTR2 in cancer cells to enhance B cell immune responses against solid tumors. This approach targets the recruitment and activation of B cells, which are crucial for improving survival outcomes in patients with advanced malignancies and autoimmune diseases.
Funding
$26M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In solid tumor treatment, insufficient B cell recruitment and activation within the tumor microenvironment limit the effectiveness of immune responses against cancer cells. Current immunotherapies often fail to fully engage the adaptive immune system, resulting in suboptimal survival outcomes for patients with advanced malignancies.
Solution
Alyssum Therapeutics is developing AT1965, a small molecule that enhances B cell immune responses against solid tumors by inhibiting CMTR2 in cancer cells. AT1965 aims to improve patient outcomes by promoting the recruitment and activation of B cells, which are crucial for a complete immune response, including direct action on cancer cells and activation of other immune cells. Preclinical studies have demonstrated that AT1965, as a monotherapy, regressed hard-to-treat solid tumors and showed synergistic effects when combined with immune checkpoint inhibitors. The modulation of B cells represents a new frontier in immunotherapy, potentially transforming the treatment of complex diseases.
Target Audience
The primary target audience includes patients with advanced solid malignancies who may benefit from enhanced B cell-mediated immune responses, as well as clinicians and researchers in the fields of oncology and immunotherapy.
Features
- AT1965: A small molecule inhibitor of CMTR2
- Designed to enhance B cell recruitment and activation in solid tumors
- Demonstrated regression of hard-to-treat solid tumors as a monotherapy in preclinical studies
- Synergistic effects with immune checkpoint inhibitors observed in preclinical models
- Currently in Phase 1 clinical trials for advanced solid malignancies